People Background Check
Find People:

Maria Constance Athanasiou, Age 59W6368 Grove St, Fond Du Lac, WI 54935

Get Report
Known as:
Maria C Athanasiou Maria Anthansiou Mari Athanasiou Naria U
Related to:
Colin T Athanasion

Maria Athanasiou Phones & Addresses

W6368 Grove St, Fond du Lac, WI 54935 (920) 921-1387

6368 W Grove St, Fond du Lac, WI 54937

181 Hoyt St, Fond du Lac, WI 54935

18 N Saint Joseph Ln, Fond du Lac, WI 54935

253 Olivia St, Derby, CT 06418

253 Olivia St #2, Derby, CT 06418

4401 Rainier St, Irving, TX 75062

3442 Belt Line Rd, Irving, TX 75062

Atlanta, GA

Saint Paul, MN

Littleton, CO

Cedar Rapids, IA

Show more

Education

School / High School: Georgetown University Law Center

Ranks

Licence: New York - Currently registered Date: 2008

Mentions for Maria Constance Athanasiou

Career records & work history

Lawyers & Attorneys

Maria Athanasiou Photo 1

Maria Athanasiou - Lawyer

Address:
Hanotiau & Van Den Berg
Licenses:
New York - Currently registered 2008
Education:
Georgetown University Law Center

License Records

Maria Athanasiou

Licenses:
License #: RN06242-T - Expired
Category: Nursing
Type: Registered Nurse-Temp Permit

Maria Athanasiou

Licenses:
License #: RN44258 - Expired
Category: Nursing
Type: Registered Nurse

Maria Athanasiou resumes & CV records

Resumes

Maria Athanasiou Photo 29

Co-Founder

Location:
Fond Du Lac, WI
Industry:
Biotechnology
Work:
Marpam Pharma
Co-Founder Pgxhealth A Division of Clinical Data Apr 2006 - Jul 2010
Vice President Athanasiou Consulting Apr 2006 - Jul 2010
Consultant Genaissance Pharmaceuticals 2000 - 2006
Senior Project Manager, Partnership Manager, Manager University of Texas Southwestern Medical Center 1997 - 2000
Associate Director of the Human Genome Center
Education:
University of Minnesota 1997
Doctorates, Doctor of Philosophy, Philosophy University of Wisconsin - Madison 1988
Bachelors, Bachelor of Science, Genetics University of Minnesota - Twin Cities
Skills:
Bioinformatics, Sequencing, Biotechnology, Personalized Medicine, Intellectual Property, Pharmacogenomics, Lifesciences, Clinical Development, Molecular Biology, Genomics, Dna Sequencing, Genetics, Due Diligence, Drug Discovery, Drug Development, Licensing, Clinical Research, Research, Biomarkers, Technical Writing, Pharmaceutical Industry, Dna, Genotyping
Maria Athanasiou Photo 30

Maria Athanasiou

Maria Athanasiou Photo 31

Maria Athanasiou

Maria Athanasiou Photo 32

Maria Athanasiou

Publications & IP owners

Us Patents

Chrna2 Genetic Markers Associated With Galantamine Response

US Patent:
2005004, Mar 3, 2005
Filed:
Jul 9, 2004
Appl. No.:
10/887650
Inventors:
Jeroen Aerssens - Wilsele, BE
Maria Athanasiou - Derby CT, US
Carlos Brain - Somerville MA, US
Nadine Cohen - Warren NJ, US
Bradley Dain - Hamden CT, US
R. Denton - Madison CT, US
Richard Judson - Guilford CT, US
Vural Ozdemir - Long Beach CA, US
Carol Reed - Bethany CT, US
International Classification:
C12Q001/68
US Classification:
435006000
Abstract:
Haplotypes in the CHRNA2 gene associated with cognitive response to galantamine treatment are disclosed. Compositions and methods for detecting and using these CHRNA2 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising galantamine or derivatives thereof that are approved for treating patients having one of these CHRNA2 haplotypes, methods and kits for predicting the response of an individual to galantamine based upon his/her haplotype profile, and methods for treating Alzheimer's patients based upon their haplotype profile.

Ephx2 Genetic Markers Associated With Galantamine

US Patent:
2005025, Nov 10, 2005
Filed:
Oct 26, 2004
Appl. No.:
10/972766
Inventors:
Jeroen Aerssens - Nieuwrode, BE
Maria Athanasiou - Derby CT, US
Carlos Brain - Somerville MA, US
Nadine Cohen - Warren NJ, US
Bradley Dain - Hamden CT, US
R. Denton - Madison CT, US
Richard Judson - Guilford CT, US
Vural Ozdemir - Long Beach CA, US
Carol Reed - Bethany CT, US
International Classification:
C12Q001/68
US Classification:
435006000
Abstract:
Haplotypes in the EPHX2 gene associated with cognitive response to galantamine treatment are disclosed. Compositions and methods for detecting and using these EPHX2 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising galantamine or derivatives thereof that are approved for treating patients having one of these EPHX2 haplotypes, methods and kits for predicting the response of an individual to galantamine based upon his/her haplotype profile, and methods for treating Alzheimer's patients based upon their haplotype profile.

Ntrk2 Genetic Markers Associated With Progression Of Alzheimer's Disease

US Patent:
2005025, Nov 10, 2005
Filed:
Nov 22, 2004
Appl. No.:
10/993509
Inventors:
Jeroen Aerssens - Nieuwrode, BE
Maria Athanasiou - Derby CT, US
Carlos Brain - Somerville MA, US
Nadine Cohen - Warren NJ, US
Bradley Dain - Hamden CT, US
R. Denton - Madison CT, US
Richard Judson - Guilford CT, US
Vural Ozdemir - Long Beach CA, US
Carol Reed - Bethany CT, US
Assignee:
Genaissance Pharmaceuticals - New Haven CT
International Classification:
C12Q001/68
US Classification:
435006000
Abstract:
Haplotypes in the NTRK2 gene associated with progression of Alzheimer's Disease are disclosed. Compositions and methods for detecting these NTRK2 haplotypes are disclosed.

Apoa4 Genetic Markers Associated With Progression Of Alzheimer's Disease

US Patent:
2005025, Nov 10, 2005
Filed:
Nov 22, 2004
Appl. No.:
10/993514
Inventors:
Jeroen Aerssens - Nieuwrode, BE
Maria Athanasiou - Derby CT, US
Carlos Brain - Somerville MA, US
Nadine Cohen - Warren NJ, US
Bradley Dain - Hamden CT, US
R. Denton - Madison CT, US
Richard Judson - Guilford CT, US
Vural Ozdemir - Long Beach CA, US
Carol Reed - Bethany CT, US
Assignee:
Genaissance Pharmaceuticals - New Haven CT
International Classification:
C12Q001/68
C12P019/34
US Classification:
435006000, 435091200
Abstract:
Haplotypes in the APOA4 gene associated with progression of Alzheimer's Disease are disclosed. Compositions and methods for detecting these APOA4 haplotypes are disclosed.

Ntrk1 Genetic Markers Associated With Age Of Onset Of Alzheimer's Disease

US Patent:
2005025, Nov 17, 2005
Filed:
Oct 13, 2004
Appl. No.:
10/962756
Inventors:
Jeroen Aerssens - Nieuwrode, BE
Maria Athanasiou - Derby CT, US
Carlos Brain - Somerville MA, US
Nadine Cohen - Warren NJ, US
Bradley Dain - Hamden CT, US
R. Denton - Madison CT, US
Richard Judson - Guilford CT, US
Vural Ozdemir - Long Beach CA, US
Carol Reed - Bethany CT, US
International Classification:
C12Q001/68
US Classification:
435006000
Abstract:
Haplotypes in the NTRK1 gene associated with age of onset of Alzheimer's Disease are disclosed. Compositions and methods for detecting and using these NTRK1 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising compounds effective in delaying the age of onset of AD in individuals at risk for developing AD and having one of these NTRK1 haplotypes, methods and kits for predicting the age of onset of AD in an individual at risk for developing AD based upon his/her haplotype profile, and methods for delaying the age of onset of AD in individuals at risk for developing AD based upon their haplotype profile.

Chrna9 Genetic Markers Associated With Progression Of Alzheimer's Disease

US Patent:
2005025, Nov 17, 2005
Filed:
Nov 22, 2004
Appl. No.:
10/993516
Inventors:
Jeroen Aerssens - Nieuwrode, BE
Maria Athanasiou - Derby CT, US
Carlos Brain - Somerville MA, US
Nadine Cohen - Warren NJ, US
Bradley Dain - Hamden CT, US
R. Denton - Madison CT, US
Richard Judson - Guilford CT, US
Vural Ozdemir - Long Beach CA, US
Carol Reed - Bethany CT, US
Assignee:
Genaissance Pharmaceuticals - New Haven CT
International Classification:
C12Q001/68
C12P019/34
US Classification:
435006000, 435091200
Abstract:
Haplotypes in the CHRNA9 gene associated with progression of Alzheimer's Disease are disclosed. Compositions and methods for detecting these CHRNA9 haplotypes are disclosed.

Cdk5 Genetic Markers Associated With Galantamine Response

US Patent:
2005025, Nov 17, 2005
Filed:
Dec 7, 2004
Appl. No.:
11/005029
Inventors:
Jeroen Aerssens - Nieuwrode, BE
Maria Athanasiou - Derby CT, US
Carlos Brain - Somerville MA, US
Nadine Cohen - Warren NJ, US
Bradley Dain - Hamden CT, US
R. Denton - Madison CT, US
Richard Judson - Guilford CT, US
Vural Ozdemir - Long Beach CA, US
Carol Reed - Bethany CT, US
International Classification:
C12Q001/68
US Classification:
435006000
Abstract:
Haplotypes in the CDK5 gene associated with cognitive response to galantamine treatment are disclosed. Compositions and methods for detecting and using these CDK5 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising galantamine or derivatives thereof that are approved for treating patients having one of these CDK5 haplotypes, methods and kits for predicting the response of an individual to galantamine based upon his/her haplotype profile, and methods for treating Alzheimer's patients based upon their haplotype profile.

Slc5A7 Genetic Markers Associated With Age Of Onset Of Alzheimer's Disease

US Patent:
2005025, Nov 17, 2005
Filed:
Dec 7, 2004
Appl. No.:
11/005030
Inventors:
Jeroen Aerssens - Nieuwrode, BE
Maria Athanasiou - Derby CT, US
Carlos Brain - Somerville MA, US
Nadine Cohen - Warren NJ, US
Bradley Dain - Hamden CT, US
R. Denton - Madison CT, US
Richard Judson - Guilford CT, US
Vural Ozdemir - Long Beach CA, US
Carol Reed - Bethany CT, US
International Classification:
C12Q001/68
US Classification:
435006000
Abstract:
Haplotypes in the SLC5A7 gene associated with age of onset of Alzheimer's Disease are disclosed. Compositions and methods for detecting and using these SLC5A7 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising compounds effective in delaying the age of onset of AD in individuals at risk for developing AD and having one of these SLC5A7 haplotypes, methods and kits for predicting the age of onset of AD in an individual at risk for developing AD based upon his/her haplotype profile, and methods for delaying the age of onset of AD in individuals at risk for developing AD based upon their haplotype profile.

Possible Relatives

John P Athanasiou  Sophia G Athanasiou  Maria E Stan  Maria J Stanek  Maria C Stange  Maria J Stanley  Maria B Starzynski  Maria D Staton  Maria E Whitley  Maria C Steen 

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.